Neuroglucopenia induced by 2-deoxy-D-glucose (2DG) activates hypothalamic glucoreceptors leading to increased hepatic glucose production and insulin inhibition. This response is similar to what is observed with intravenous injection of angiotensin II (Ang II). However, the involvement of an angiotensin-converting enzyme inhibitor on neuroglucopenia has not been investigated. The aim of this study was to determine the effects of chronic enalapril treatment on plasma glucose, insulin and lipid levels in response to neuroglucopenia. Male Holtzman rats (120-170 g) were chronically treated with enalapril (10 mg/kg per day) in the drinking water for two weeks. On the day of experiment the animals received an i.v. enalapril final dose one hour before the neuroglucopenic stress by 2DG infusion (500 mg/kg), and blood samples were drawn before and 5, 10, 20, 30 and 60 minutes following infusion. The hyperglycaemic response to 2DG was not significantly changed by enalapril treatment. The enalapril-treated group exhibited a peak of plasma insulin higher than controls. Plasma triglyceride showed a significant increase only in the enalapril group after neuroglucopenic stress (p < 0.05). These data show that chronic enalapril treatment changes insulin and triglyceride responses to neuroglucopenia, suggesting an effect on glucose-induced insulin secretion and the storage of triglycerides.
Introduction
The metabolic actions of the renin-angiotensin system (RAS) have been the target of several studies. Its participation in the metabolic response to stress was previously described for both acute and chronic forms of stress as a result of haemorrhage 1 and immobilisation. [2] [3] [4] However, the data obtained so far refer to the direct blockade of angiotensin II receptors. Despite clinical studies demonstrating that inhibition of the angiotensin-converting enzyme (ACE) has beneficial effects on carbohydrate metabolism, 5 little is known about the role of ACE inhibitors on acute stresses and their interactions with lipid metabolism.
2-Deoxy-d-glucose (2DG) is a non-metabolisable analog of glucose that effectively blocks glucose utilisation by neurons. Its peripheral infusion produces neuroglucopenia, which induces activation of hypothalamic glucoreceptors with a consequent rise in the sympathetic output to the liver, pancreas, adrenal medulla and adipose tissue, resulting in increased hepatic production of glucose, inhibition of insulin secretion and mobilisation of free fatty acids from adipose tissue. [6] [7] [8] The aim of this study was to investigate the effects of the chronic administration of enalapril, an ACE inhibitor, on plasma glucose levels, insulin, triglycerides and cholesterol in rats submitted to acute neuroglucopenic stress by 2DG infusion. We expected a priori that ACE inhibition would stimulate the glucose-induced insulin secretion and possibly interfere with plasma triglycerides in response to neuroglucopenia. We have shown here that treatment with enalapril was able to change insulin and triglyceride responses to an acute neuroglucopenic challenge, confirming our initial hypothesis.
Materials and methods Animals
Male Holtzman rats (120-170 g), provided by the Federal University of Minas Gerais Medical School Central Animal Facility, were maintained under temperature-controlled conditions with an artificial 12-h light-dark cycle, and allowed standard chow and water ad libitum. The University Ethics Committee for Animal Experiments approved all procedures.
Experimental design
Protocol 1: effect of long-term administration of enalapril on body weight and drinking adherence. Rats were placed in individual cages and treated with enalapril maleate (Merck, São Paulo, Brazil) in drinking water (5% solution, 10 mg/ kg per day) for 2 weeks or no addition (vehicle) for the same period, according to a well-established protocol. 9 The same protocol of enalapril administration was previously used by Britto et al., whose data have shown an effective blockade of ACE. 9 In order to address the role of the chronic enalapril treatment upon body weight and drinking adherence, daily liquid intake and body weights of enalapriltreated and control rats were recorded.
Protocol 2: effect of long term-administration of enalapril on metabolic response to neuroglucopenic stress by 2DG infusion.
Two days before the experiments, rats on chronic enalapril treatment for two weeks and controls were anaesthetised, and a silastic catheter (0.5 mm DI, 0.94 mm DE, N°602-135; Dow Corning Corporation, Auburn, MI, USA) was inserted through the jugular vein into the right atrium for blood sampling and drug administration. 10 One hour before the induction of neuroglucopenic stress, the enalapriltreated animals received a single intra-venous dose of 5 mg/kg enalapril maleate diluted in NaCl 0.9% (5% solution), 9 whereas control rats were given a single dose of NaCl 0.9%. This last dose was administered to assure high circulating enalapril concentrations during the experiments. Then, the animals were returned to their home cages and allowed to rest for 60 min. At the end of the rest period, baseline samples were collected via the atrial catheter immediately before the induction of neuroglucopenic stress or vehicle infusion, and further 0.6 ml blood samples were collected at 5, 10, 20, 30 and 60 min following the infusions. Plasma volume was restored by saline injection after every blood collection.
The experiments were all carried out between 08:00 a.m and 12:00 p.m. in a quiet experimental room equipped for performing stress experiments under temperature control. Neuroglucopenic stress was induced by infusion of 50 mg/100 g of 2-deoxy-D-glucose 10% solution. 8 The animals were divided into three experimental groups: control rats submitted to neuroglucopenic stress (VD), enalapriltreated rats subjected to neuroglucopenic stress (ED), and enalapril-treated rats receiving NaCl 0.9% infusion instead of 2DG solution (ES).
Assays
All metabolic and hormone parameters were assayed in duplicate. Glucose was assayed by glucose oxidase method (GOD-ANA, CENTERLAB, Santa Luzia, Minas Gerais, Brazil), and lipids (triglycerides and cholesterol) were assayed by enzymatic method (CENTERLAB, Santa Luzia, Minas Gerais, Brazil). Insulin was measured by radioimmunoassay (SRI-13K, Linco Research, St Charles, MO, USA), using rat insulin I 125 -labelled and rat anti insulin serum as the antibody of the assay. All insulin measurements were assayed in a single assay to avoid inter-assay variation. Our average intra-assay variation was 5%.
Statistical analysis
The results were expressed as mean ± standard error of the mean (SEM). The samples obtained before and after neuroglucopenic stress were compared by Student's paired t-test. Differences between the groups were determined using ANOVA followed by the Holm Sidak test. The areas under glucose, insulin, triglyceride and cholesterol curves were integrated by the trapezium rule and compared by ANOVA followed by Student t-test. Values of p < 0.05 were considered significant.
Results

Effect of long-term administration of enalapril on body weight and drinking adherence
Enalapril treatment did not change water intake volume or weight gain in the enalapril-treated animals when compared with control animals (table 1). There was no difference between the two-week fluid intake of animals who on the day of the neuroglucopenic stress were assigned to stress or to control groups, suggesting that they had equal exposure to enalapril.
Effects of 2DG injection on plasma glucose levels of enalapril-treated rats
There was a marked increase in plasma glucose levels for both groups (VD and ED) submitted to 2DG infusion, which was already significant at 5 min (p < 0.01), and reached a peak at 30 min in CD group (306.5 ± 22.8 mg/dl) and at 60 min in ED group (310.3 ± 28.7 mg/dl). No significant changes were found between VD and ED groups during the 60 min stress protocol (p > 0.05, figure 1A ). Baseline plasma glucose levels were similar in enalapril-treated rats (groups ED and ES) when compared with VD group (p > 0.05 for all comparisons).
The comparison between areas under glucose curves of stressed animals (ED and VD groups) did not show significant differences (figure 1B).
Effects of 2DG injection on plasma insulin levels of enalapril-treated rats
As observed in figure 2, saline infusion did not change plasma insulin levels. However, 2DG infusion decreased plasma insulin levels in the stressed control group (VD), reaching a small but significant reduction at 5 min after infusion (p < 0.05) despite the huge increase of plasma Figure 1 . A. Effects of neurocytoglucopenic stress on plasma glucose levels (absolute values) in rats chronically treated with enalapril. The values represent the mean ± SEM of the individual observations for each of the groups: VD (10 rats chronically treated with vehicle and submitted to 2DG stress); ED (10 rats chronically treated with enalapril and submitted to neurocytoglucopenic stress); ES (7 rats chronically treated with enalapril and submitted to saline infusion). glucose levels. Following this initial period, insulin levels of this group recovered to basal values after a brief trend toward an increase at 30 min. In sharp contrast, enalapril-treated rats submitted to neurocytoglucopenic stress (ED group) did not show decreased plasma insulin levels. This group otherwise, exhibited a significant increase of insulin levels with a peak at 30 min (1.13 ± 0.26 ng/ml), differing significantly at this time point from VD group (p < 0.05). Enalapril-treated animals (ED and ES group) did not show significant differences in baseline plasma insulin levels when compared with controls (p > 0.05, for both comparisons). The analysis of the areas under the plasma insulin curves reveal significant differences between groups, showing higher insulin levels in enalapril-treated stressed rats (ED group), whereas the control animals submitted to 2DG infusion did not significantly differ from the ES group ( figure 2B ).
Effects of 2DG injection on plasma triglycerides of enalapril-treated rats
After 2DG infusion, an accentuated and long-lasting rise in plasma triglyceride levels in the ED group was observed, reaching a peak at 10 min (33.8 ± 6.8 mg/dl, p < 0.05 when compared with baseline levels). In contrast to the ED group, plasma triglyceride showed no differences in both other groups. Enalapril-treated animals (ED and ES groups) did not show significant differences in baseline plasma triglyceride levels when compared with VD group (p > 0.05 for all comparisons).
As displayed in figure 3B , the comparison between the areas under the triglyceride curves showed significant differences between enalapril-treated animals submitted to neuroglucopenic stress (ED group) and the other groups (VD and ES).
Effects of 2DG injection on plasma cholesterol levels of enalapril-treated rats
The three experimental groups (VD, ED and ES) did not exhibit significant differences in baseline cholesterol values (p > 0.05, table 1). No significant changes were detected in cholesterol levels after 2DG or saline infusion in all experimental groups (p > 0.05, figure 4A ). As anticipated, the comparison between the areas under the cholesterol curves confirmed the absence of differences among the studied groups ( figure 4B ).
Discussion
The role of RAS in metabolic homeostasis has been studied due to the widespread use of RAS inhibitors in clinical practice. [11] [12] [13] However, few studies have evaluated the RAS Figure 2 . A. Effects of neurocytoglucopenic stress on plasma insulin levels (absolute values) in rats chronically treated with enalapril. The values represent the mean ± SEM of the individual observations for each of the groups: VD (10 rats chronically treated with vehicle and submitted to 2DG stress); ED (10 rats chronically treated with enalapril and submitted to 2DG stress); ES (7 rats chronically treated with enalapril and submitted to saline infusion). during stressful acute events. 3, 4, [14] [15] [16] [17] In the present study, chronic treatment with the ACE inhibitor enalapril did not alter the baseline levels of plasma glucose, insulin, triglycerides and cholesterol. In addition, the two-week period of enalapril administration did not change the water intake and weight gain of the animals, despite the possible interference with angiotensin II dipsogenic effects. 18 On the other hand, the chronic treatment with enalapril changed the pattern of plasma insulin secretion and triglycerides release due to neuroglucopenia, whereas plasma cholesterol levels and the hyperglycaemic response to neuroglucopenia were not significantly influenced by enalapril administration.
The mechanisms involved in the metabolic effects of ACE inhibition are poorly known. The reduction of angiotensin II probably plays a role in these effects. However, besides reducing angiotensin II synthesis, some actions of ACE inhibitors have been attributed to the rise in bradykinin and in angiotensin-(1-7) levels. [19] [20] [21] [22] Interestingly, bradykinin also exhibits well-known effects on glucose metabolism, acting on peripheral insulin activity and facilitating insulin-induced glucose uptake. 19, 23 Our data regarding plasma insulin secretion also should be considered in the light of the local tissue RAS systems, which have been identified in most organs, covering both endocrine, paracrine and intracrine functions. More importantly, a local pancreatic RAS tissue has been described acting on endocrine and exocrine functions. 24, 25 Carlsson et al. have demonstrated that the use of enalaprilat (an active enalapril metabolite) and saralasin (an angiotensin II antagonist) increases pancreatic blood flow, while angiotensin II infusion conversely reduces the same flow, possibly affecting the first phase insulin secretion. 26 Likewise, Lupi et al. have recently shown that RAS molecules are present in islets where their expression is sensitive to glucose concentration, and that ACE inhibitors protect human islets from glucotoxicity. 27 Furthermore, there has been mounting evidence for angiotensin II participation in glucose metabolism. 5, 28, 29 Data coming from our group and others point to an attenuating action of the hyperglycaemic response to stress associated with the use of angiotensin II receptor antagonists. 4, 15 Prominent evidence points to a major AT1 receptor angiotensin II participation in haemorrhagic and immobilisation stresses. 3, 4, 14, 17 Yang et al. have demonstrated increased angiotensin II levels in several models of stress in rats, possibly due to an increase of renal sympathetic activity releasing renin, but also because of the actions of angiotensin II upon the sympathetic adrenal and hypothalamus-pituitaryadrenal axis. 30 Interestingly, Bregonzio et al. and Talas and Yurekli have shown that angiotensin receptor blockers and enalapril treatment were able to prevent the increase of tyrosine hydroxylase activity in the adrenal medulla of rats exposed to cold stress, suggesting a possible attenuation of insulinmediated inhibition of noradrenaline release by these treatments. 16, 31 Our data from the present study showed that plasma insulin response to neuroglucopenic stress was modified by enalapril treatment although no significant change in the hyperglycaemic stress response could be observed. We postulate that the chronic treatment with enalapril might have attenuated the sympathetic effect on insulin secretion, very likely by potentiating glucoseinduced insulin secretion in this experiment. Alternatively, a role for glucagon in the hyperglycaemic response to 2DG infusion and its regulation by noradrenergic pathways could also be involved in this stress response regulation. 32 After 2DG infusion, both stressed groups, enalapriltreated or not, showed an early and sustained hyperglycaemic response. This extreme hyperglycaemic response to neurocytoglucopenic stress was previously reported by our group and others, corroborating the pronounced hyperglycaemic effect of intravenous 2DG infusion. 8, 33 Altogether these effects, coupled to the aforementioned interference in noradrenergic pathways, may explain the altered sympathetic-adrenal axis response accounting for the changes observed in the response of plasma insulin of the enalapril-treated stressed animals. Likewise, it was recently shown in obese subjects that enalapril treatment reduced sympathetic activity. 34 Similar data have been described with chronic bromocriptine treatment increasing parasympathetic response to neuroglucopenic stress. 8 In the present study, it has also been observed that plasma triglyceride neuroglucopenic stress response was significantly modified by the chronic enalapril treatment. In enalapril-treated rats, an increase in triglyceride levels was observed after 2DG infusion while the controls showed no alteration of plasma triglyceride levels. These data point towards a major RAS role on the response of triglyceride metabolism to neuroglucopenic stress. Although still controversial, there are other studies that support a decrease in triglyceride levels during stress. [35] [36] [37] Neuroglucopenia, like other stress models, is related to high catecholamine levels that activate adipose hormonesensitive tissue lipase, ultimately leading to prompt triglyceride mobilisation for the plasma. 38 On the other hand, the triglyceride degradation is performed by the endothelial lipoprotein lipase acting on triglycerides to release free fatty acids into the blood stream. During stress, the activity of this lipoprotein lipase is, apparently, tissue-specific and is inhibited in adipose tissue but activated in muscular tissue. 39 Thus, the adipose tissue takes up its function as an energy supplier to the other tissues, especially muscular tissue, which degrades triglycerides and captures free fatty acids, using them as an energy source. Our data suggest a change in this triglyceride response to neuroglucopenic stress by the chronic enalapril treatment. We, however, hypothesise that the chronic treatment with enalapril might have shut down the lipoprotein lipase activity. Further studies including free fatty acids (FFA) measurements should help clarify this issue, as a decrease in FFA is expected in the enalapril-treated stressed group. Otherwise, the 2DG neurocytoglucopenic stress as well as the chronic enalapril treatment did not show a significant change in plasma cholesterol levels, which remained constant throughout the experimental period, providing further evidence for no significant changes of cholesterol following a stress challenge. 35 To the best of our knowledge, this study shows for the first time the influence of chronic enalapril treatment on carbohydrate and lipid metabolism in rats exposed to neuroglucopenia. These new data concerning the influence of enalapril upon neuroglucopenic metabolic response shed light on the understanding of how an early response elicited by the chronic ACE inhibition during an acute stressful event may be related to sudden changes in metabolic regulation. We, however, emphasise that the early metabolic changes in neuroglucopenic stress response shown here may be helpful for understanding pathways involved in ACE inhibition during acute stress events generally .
Conclusions
These data show that chronic enalapril treatment changes insulin and triglyceride responses to neuroglucopenia, suggesting an effect on glucose-induced insulin secretion and the storage of triglycerides.
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